Literature DB >> 10533061

Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects.

S Tuffery-Giraud1, S Chambert, J Demaille, M Claustres.   

Abstract

Ten different mutations have been identified in patients with Becker (n = 1) or Duchenne (n = 9) muscular dystrophy using reverse transcription of total RNA, polymerase chain reaction amplification of the whole coding region of the gene and protein truncation test (PTT) analysis. Seven mutations had not been reported previously, and these consist in three nonsense mutations (Q2522X, E2726X, R3381X), three frameshifting deletions (3686-3687delGT, 5126delA, 5759delC), and four splicing defects of which the effects on the muscle dystrophin mRNA transcripts have been analyzed. In one case, a 3' splice-site mutation (IVS74-2A-->G) resulted in a complex pattern of exon skipping involving exons of the C-terminal domain. In the three other cases, nucleotide substitutions in splice donor (IVS26+2T-->A, IVS65+1G-->A) or acceptor (IVS8-15A-->G) recognition sequences led to the use of cryptic splice sites, with consequent insertions of intronic sequences in the processed mRNA. Up to 34% (70/203) of the point mutations reported to date in the dystrophin database (http://www.dmd.nl) affect splice sites of the dystrophin gene. However, altered mRNA splicing has been confirmed experimentally in only 23% of cases (16/70). Combined with PTT, the transcript analysis protocol defined in this study permits direct determination of the impact of intronic variations on the structure of dystrophin mRNA and of the resulting consequences on the translational reading frame. We present evidence for a frequent use of cryptic splice sites as a result of splicing defects. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10533061     DOI: 10.1002/(SICI)1098-1004(199911)14:5<359::AID-HUMU1>3.0.CO;2-K

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  15 in total

Review 1.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

2.  Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.

Authors:  Jeyakumar Kandasamy; Dana Atia-Glikin; Eli Shulman; Katya Shapira; Michal Shavit; Valery Belakhov; Timor Baasov
Journal:  J Med Chem       Date:  2012-11-29       Impact factor: 7.446

3.  Molecular nature of 11 spontaneous de novo mutations in Drosophila melanogaster.

Authors:  H P Yang; A Y Tanikawa; A S Kondrashov
Journal:  Genetics       Date:  2001-03       Impact factor: 4.562

4.  Evolution of the exon-intron structure and alternative splicing of the MAGE-A family of cancer/testis antigens.

Authors:  Irena I Artamonova; Mikhail S Gelfand
Journal:  J Mol Evol       Date:  2004-11       Impact factor: 2.395

Review 5.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

6.  Microarray-based mutation detection in the dystrophin gene.

Authors:  Madhuri R Hegde; Ephrem L H Chin; Jennifer G Mulle; David T Okou; Stephen T Warren; Michael E Zwick
Journal:  Hum Mutat       Date:  2008-09       Impact factor: 4.878

7.  Mini-dystrophin efficiently incorporates into the dystrophin protein complex in living cells.

Authors:  Romesh A Draviam; Bing Wang; Juan Li; Xiao Xiao; Simon C Watkins
Journal:  J Muscle Res Cell Motil       Date:  2006-02-23       Impact factor: 2.698

8.  Rapid direct sequence analysis of the dystrophin gene.

Authors:  Kevin M Flanigan; Andrew von Niederhausern; Diane M Dunn; Jonathan Alder; Jerry R Mendell; Robert B Weiss
Journal:  Am J Hum Genet       Date:  2003-03-11       Impact factor: 11.025

9.  MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.

Authors:  Alexander Drilon
Journal:  Clin Cancer Res       Date:  2016-03-23       Impact factor: 12.531

10.  New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations.

Authors:  Keisuke Hamada; Noriko Omura; Akihiro Taguchi; Alireza Baradaran-Heravi; Masaya Kotake; Misaki Arai; Kentaro Takayama; Atsuhiko Taniguchi; Michel Roberge; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2019-09-23       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.